AgomAb Therapeutics (AGMB) Director Epstein Buys $89K of Stock

AgomAb Therapeutics NV director David R Epstein picked up 10,000 shares of the clinical-stage biopharmaceutical firm on October 21, 2026. The transaction was revealed in a Form 4 filing with the Securities and Exchange Commission.

AGMB AgomAb Therapeutics NV

$9.11 ▼ -21.74% past 3 months

1M 3M

Daily close · Oct 21, 2026

Inside David R Epstein's AGMB Trade

Epstein bought the shares at a price of $8.88 each, spending a total of $88,800 on the open-market purchase. The trade grew his direct holdings to 25,000 shares, marking a 66.67% increase in his personal stake. The stock closed at $9.11 on the day of the trade.

Other Institutional Activity in AgomAb Therapeutics NV

Large financial funds hold major stakes in the biotech company alongside insiders. Eqt Fund Management S.a R.l. held 5,141,992 shares worth about $46,835,455 as of June 30, 2026, making no changes to its position. Sanofi kept its holdings steady at 2,783,096 shares valued at roughly $25,354,003. Redmile Group, LLC significantly expanded its investment, adding 2,577,676 shares to end with 2,733,926 shares worth about $24,906,064, which is a 1,649.7% increase. Cormorant Asset Management, LP maintained 2,465,348 shares valued at roughly $22,459,319. TCG Crossover Management, LLC held 2,053,233 shares worth about $18,704,951 with no change over the period.

AgomAb Therapeutics NV Stock Up 4.5%

Shares recently traded around $9.12 as of October 22, 2026, which is up about 0.1% from the event close and roughly 15.2% above its 52-week low of $7.92. The stock sits below its 50-day moving average of $11.66 and its 200-day moving average of $12.25.

Recent Earnings

The company is a clinical-stage developer of treatments for immunology and inflammatory diseases, which means it currently spends heavily on research rather than generating product revenue. It posted a trailing twelve-month loss per share of $2.08.

Insider Buying and Selling at AgomAb Therapeutics NV

Company insiders have shown consistent buying interest in recent months. Director David R Epstein previously picked up 10,000 shares on October 6, 2026, in a transaction valued at $86,350. Chief Financial Officer Pierre Kemula bought 10,000 shares worth $85,940 on the same day, while Chief Executive Officer Tim Jasper Knotnerus added 11,000 shares for $94,380.

Analysts Set New Price Targets

Wall Street analysts keep a positive outlook on the company. B. Riley Securities initiated coverage with a Buy rating and a $34.00 price target on July 23, 2026. Cantor Fitzgerald started coverage with an Overweight rating on August 19, 2026. Piper Sandler initiated an Overweight rating with a $60.00 price target on August 25, 2026. The stock currently holds a strong buy consensus rating among six analysts.

About AgomAb Therapeutics NV

AgomAb Therapeutics NV is based in Antwerp, Belgium, and employs 62 people. The company focuses on discovering and developing novel disease-modifying therapies to address immunology and inflammatory conditions in the United States and international markets.

Bottom Line

Insider transactions provide a window into how leadership views the company's long-term pipeline progress. Investors will watch for upcoming clinical milestones and future SEC disclosures to track further insider activity.